DTIL

DTIL is a pre-commercial ARCUS gene-editing company whose income statement is entirely collaboration accounting, not product sales. FY2025 revenue fell 50.1% to $34.3M as the Novartis and Prevail collaborations wound down, and the reported FY2024 net income of +$7.2M — the only profitable year in the five-year history — was a deferred-revenue artifact that reversed hard to a -$45.7M loss in FY2025. Operating margin is -152%, ROE -49.6%, and the accumulated deficit stands at -$528M. There is no durable revenue engine here; the P/S of 5.9x is meaningless against revenue that is lumpy, milestone-driven and shrinking.

The balance sheet buys time but the cost is dilution. Cash of $111M ($137.2M including restricted) against a -$65.8M operating burn implies management's stated runway 'through 2028' leans on azer-cel milestones plus continued ATM sales. That runway was itself manufactured by a November 2025 public offering with warrants that drove shares outstanding up 135.9% year-over-year to 24.7M — existing holders were cut roughly in half in a single year, and the ATM facility signals more of the same. Liabilities/equity of 0.67x and a strong current ratio are fine, but for a cash-burning clinical biotech the relevant metric is months of runway versus dilution, and that math is unfavorable.